Abstract:The producers of medical technology constantly strive to innovate and to improve their products for the benefit of patients. With each new generation of devices enabling less invasive techniques, better clinical outcomes and reduced recovery times, patients are direct beneficiaries of this commitment to innovation. Innovation and patient access to technology are inseparably linked with each national health system's respective coverage, procurement and reimbursement policies. If a particular innovation is not included in the basket of services covered by public resources, there may be a time lag before it enters the system and reaches patients. If the procurement criteria focus primarily on price, it is likely that the quality and innovativeness will be penalised. Finally, if the use of an innovative technology leads to higher costs for the health-care provider, it has to bear the cost until the reimbursement mechanism is updated to include the new technology. Today there are substantial regional differences relative to the financial incentives for introducing new technology and in some cases, it can take years before the new technologies are recognised, which can inhibit the roll-out of innovation within the health system. In addition to utilising different policy choices for funding and procurement, the decision-making criteria used to inform policies vary greatly in European countries. Increasingly, health-care policymakers want scientific, technological and economic evidence before classifying a new technology as reimbursable. Although it is important to ensure that new medical devices are superior to conventional treatments, due to short-sightedness in certain assessment mechanisms and limited availability of clinical trial information, the reliability of estimates of the efficacy and cost-effectiveness can be questioned. As health technology assessment procedures are centralised, it becomes ever more important that coverage decisions regarding new medical devices are made on sound, robust criteria and that they include the full economic benefits – to the patient, to the health-care system and to society – of innovative new technology. As pressure on health-care funding mounts, reimbursement policy, in particular, is being refocused to target the contrasting objectives of healthcare expenditure containment and support of innovation. Looking forward, the successful balancing of technological adoption and affordability will require a judicious use of policy levers and will probably be accompanied by more regulatory action.

The Intersection Of Prescription Drugs And Medical Devices: The Evaluation And Funding Challenges Of Two Categories Of Emerging Health Technologies

Electronically Powered Drug Delivery Devices: Considerations and Challenges

Integration of personalized drug delivery systems into digital health

Evaluation of diagnostic imaging technologies and therapeutics devices: better information for better decisions: proceedings of a multidisciplinary workshop

The medical device development ecosystem: Current regulatory state and challenges for future development: A review

Opportunities and challenges for innovative and equitable healthcare

Integrated Devices: A New Regulatory Pathway to Promote Revolutionary Innovation

Health Technology Assessment of Medical Devices: Current Landscape, Challenges, and a Way Forward

Digital technologies: Innovations that transform the face of drug development

Identification of Medical Key Technology Frontiers by Patent Analysis

Device regulation and surveillance in vascular care: Challenges and opportunities

Challenges in the Assessment of Medical Devices: The MedtecHTA Project

Question-based drug development and the value of novel treatments

Evaluating the Safety Profile of Non-Active Implantable Medical Devices Compared with Medicines

Emerging technologies and their impact on regulatory science

Preclinical and Clinical Studies Supporting Development of Drug + Digital Combination Therapies for Chronic Diseases

Evolving regulatory perspectives on digital health technologies for medicinal product development

Regulatory strategies for early device development and approval

Uptake and diffusion of medical technology innovation in Europe: What role for funding and procurement policies?

Doctors as Device Manufacturers? Regulation of Clinician-Generated Innovation in the ICU

Adverse Events in the Digital Age: Finding the Sharpest Tool in the Box